Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: resection Clear all
Recruiting No phase listed Observational

EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)

NCT03369821
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Beta Cell Loss and Immune Function, Immune Function with RNAseq
Diagnostic Test · Other
Lead sponsor
University of Exeter
Other
Eligibility
Up to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 10, 2026, 4:39 PM EDT
Active, not recruiting Phase 2 Interventional

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

NCT05836584
View directory record Official record
Conditions
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Atezolizumab, Biospecimen Collection, Capecitabine, Computed Tomography, Docetaxel, Echocardiography Test, Fluorouracil, Leucovorin Calcium, Lymphadenectomy, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Surgical Procedure
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
133
States / cities
Dublin, California • Fremont, California • Fresno, California + 99 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 10, 2026, 4:39 PM EDT
Terminated Phase 2Phase 3 Interventional

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

NCT02414165
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Toca 511, Toca FC, Lomustine, Temozolomide, Bevacizumab
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 10, 2026, 4:39 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Dietary Sugar Absorptive Phenotype for Prediction of Weight Loss Outcome

NCT05408728
View directory record Official record
Conditions
Obese, Healthy, Bariatric Surgery Candidate
Interventions
Endoscopic biopsy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 10, 2026, 4:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

NCT00193128
View directory record Official record
Conditions
Esophagus Cancer
Interventions
Oxaliplatin, Docetaxel, Capecitabine, Radiation therapy
Drug · Radiation
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
7
States / cities
Beverly Hills, California • Jacksonville, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 10, 2026, 4:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Use of a Novel Microbicidal Liquid Polymer for the Reduction of Pin Track Infection

NCT03756506
View directory record Official record
Conditions
Infection, Post-operative Care
Interventions
Novel Microbicidal Liquid Polymer
Device
Lead sponsor
Prevent-Plus LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 10, 2026, 4:39 PM EDT
Terminated Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

NCT00042952
View directory record Official record
Conditions
Ovarian Dysgerminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage II Malignant Testicular Germ Cell Tumor, Stage II Ovarian Germ Cell Tumor, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Testicular Seminoma
Interventions
imatinib mesylate, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 10, 2026, 4:39 PM EDT
Completed Phase 4 Interventional

Magseed Magnetic Marker in Locating Axillary Lymph Nodes in Patients With Breast Cancer Undergoing Surgery

NCT03038152
View directory record Official record
Conditions
Breast Carcinoma Metastatic in Lymph Node, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7
Interventions
Axillary Lymph Node Dissection, Localization, Medical Device
Procedure · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 10, 2026, 4:39 PM EDT
Terminated Not applicable Interventional Results available

Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy

NCT01938716
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Sep 10, 2026, 4:39 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Maneuvers to Reduce Laparoscopic Pain

NCT07583433
View directory record Official record
Conditions
Laparoscopic Surgery, Post Operative Pain, Acute, Pneumoperitoneum
Interventions
Smoke Evacuation Group, Recruitment Breath Group, Control Group
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 10, 2026, 4:39 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Prevention of NAFLD in Hispanic Children

NCT05292352
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
LFSD
Behavioral
Lead sponsor
Emory University
Other
Eligibility
6 Years to 9 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 10, 2026, 4:39 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

NCT03383458
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
Nivolumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
28
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 10, 2026, 4:39 PM EDT
Terminated Phase 1 Interventional

Mapping Draining Lymph Nodes in CNS Malignancies

NCT04096716
View directory record Official record
Conditions
Central Nervous System Neoplasms, Central Nervous System Tumor
Interventions
Tc-99m tilmanocept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 10, 2026, 4:39 PM EDT
Completed Not applicable Interventional

A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection

NCT01645852
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Hepatic Steatosis, Steatohepatitis
Interventions
Optifast 800
Dietary Supplement
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Worcester, Massachusetts • Lebanon, New Hampshire • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 10, 2026, 4:39 PM EDT
Recruiting Phase 1 Interventional

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

NCT06483048
View directory record Official record
Conditions
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Carcinosarcoma, Recurrent Female Reproductive System Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinosarcoma, Refractory Fallopian Tube Carcinoma, Refractory Female Reproductive System Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
Interventions
Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 10, 2026, 4:39 PM EDT
Completed Not applicable Interventional Results available

Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation

NCT01569763
View directory record Official record
Conditions
Menorrhagia
Interventions
Aurora Endometrial Ablation, Rollerball Ablation/Resection
Device
Lead sponsor
Minerva Surgical, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
8
States / cities
Chandler, Arizona • Phoenix, Arizona • Newburgh, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 10, 2026, 4:39 PM EDT
Enrolling by invitation No phase listed Observational

Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

NCT03226704
View directory record Official record
Conditions
Leukemia, Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Leukapheresis
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 10, 2026, 4:39 PM EDT
Terminated Phase 2 Interventional Results available

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

NCT04965311
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 10, 2026, 4:39 PM EDT
Completed Phase 2 Interventional

Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma

NCT00183911
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastric Cancer
Interventions
floxuridine, 5-Fluorouracil, leucovorin, External Beam Radiotherapy, Surgery
Drug · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 10, 2026, 4:39 PM EDT
Recruiting Phase 2 Interventional

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

NCT07061964
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Transurethral Resection of Bladder Tumor
Procedure · Biological · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
165
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 130 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 10, 2026, 4:39 PM EDT
Recruiting Phase 2 Interventional

A Study of LY4515100 in Participants With Pain Following Third Molar Removal

NCT07511816
View directory record Official record
Conditions
Acute Pain, Molar, Molar, Third, Surgery, Oral
Interventions
LY4515100, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 40 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 10, 2026, 4:39 PM EDT
Recruiting Phase 1 Interventional

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

NCT04185038
View directory record Official record
Conditions
Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Ependymoma, Medulloblastoma, Childhood, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma, Childhood, Glioma
Interventions
SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 26 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2042
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 10, 2026, 4:39 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Microbiome in Colorectal Cancer Onset and Progression

NCT05368688
View directory record Official record
Conditions
Colorectal Cancer, Tumor, CRC, GI Cancer, Gastrointestinal Cancer
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
50 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced Sep 10, 2026, 4:39 PM EDT
Recruiting Early Phase 1 Interventional

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

NCT06664151
View directory record Official record
Conditions
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
Interventions
Fluzone Trivalent
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 10, 2026, 4:39 PM EDT